Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Retained Earnings (2016 - 2025)

Haemonetics has reported Retained Earnings over the past 16 years, most recently at -$34.6 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$34.6 million for Q4 2025, down 108.82% from a year ago — trailing twelve months through Dec 2025 was -$34.6 million (down 108.82% YoY), and the annual figure for FY2025 was $352.2 million, up 1088.36%.
  • Retained Earnings for Q4 2025 was -$34.6 million at Haemonetics, down from $336.3 million in the prior quarter.
  • Over the last five years, Retained Earnings for HAE hit a ceiling of $392.2 million in Q4 2024 and a floor of -$42.7 million in Q2 2024.
  • Median Retained Earnings over the past 5 years was $72.5 million (2021), compared with a mean of $127.0 million.
  • Biggest five-year swings in Retained Earnings: crashed 123.76% in 2022 and later surged 1708.69% in 2024.
  • Haemonetics' Retained Earnings stood at $169.4 million in 2021, then soared by 32.09% to $223.8 million in 2022, then tumbled by 110.9% to -$24.4 million in 2023, then surged by 1708.69% to $392.2 million in 2024, then crashed by 108.82% to -$34.6 million in 2025.
  • The last three reported values for Retained Earnings were -$34.6 million (Q4 2025), $336.3 million (Q3 2025), and $356.0 million (Q2 2025) per Business Quant data.